Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus Reports Third Quarter 2024 Results

Business Wire November 6, 2024

Evolus to Participate in Stifel 2024 Healthcare Conference

Business Wire November 1, 2024

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Business Wire October 31, 2024

Evolus Rewards(TM) Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Business Wire October 29, 2024

Evolus to Report Third Quarter Financial Results on November 6, 2024

Business Wire October 23, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 11, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 27, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Business Wire September 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 9, 2024

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Business Wire July 31, 2024

Evolus to Hold Investor Day on September 12, 2024

Business Wire July 31, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Business Wire July 30, 2024

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire July 25, 2024

Evolus to Report Second Quarter Financial Results on July 31, 2024

Business Wire July 17, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Business Wire July 1, 2024

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse(TM) Dermal Filler Products

Business Wire June 24, 2024

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Business Wire June 12, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 7, 2024

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE Meeting

Business Wire May 20, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 10, 2024